ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3926-3934

  Johnson, Bruce E ^a   Kabbinavar, Fairooz ^b   Fehrenbacher, Louis ^c   Hainsworth, John ^e   Kasubhai, Saifuddin ^f   Kressel, Bruce ^g   Lin, Chin Yu ^d   Marsland, Thomas ^h   Patel, Taral ^j   Polikoff, Jonathan ^c   Rubin, Mark ⁱ   White, Leonard ^k   Yang, James Chih Hsin ^m   Bowden, Chris ^d   Miller, Vincent ^l  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

^d GENENTECH INC   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f Northwest Medical Specialties   (United States)

^g Sibley Memorial Hospital   (United States)

^h Integrated Community Oncology Network   (United States)

ⁱ Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^j Mark H Zangmeister Center   (United States)

^k Center for Cancer Care and Research   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; PLACEBO; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADD ON THERAPY; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATLAS; BLINDNESS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; CYTODIAGNOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LARGE CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG TUMOR; MAINTENANCE CHEMOTHERAPY; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84891656497     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.3983     Document Type: Article

References (19)

1. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
2. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27:1227-1234, 2009
3. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809, 2010
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
5. Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest 136:260-271, 2009
6. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005
7. Herbst RS, O'Neill VJ, Fehrenbacher L, et al: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 25:4743-4750, 2007 (Pubitemid 350086476)
8. Herbst RS, Ansari R, Bustin F, et al: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 377:1846-1854, 2011
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
10. Westfall PH, Krishen A: Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Inference 99:25-40, 2001 (Pubitemid 33619467)
11. Brugger W, Triller N, Blasinska-Morawiec M, et al: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120, 2011
12. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multi-centre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
13. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
14. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
15. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
16. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
17. Barlesi F, de Castro J, Dvornichenko V, et al: Final efficacy outcomes for patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1l) bev-cisplatin (cis)-pem treatment (Tx). European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011 (abstr 34LBA)
18. Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247-255, 2012
19. Paz-Ares L, de Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl 18s; abstr LBA7507)